Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Medication Talk - Expert Insights on Drug Therapy & Patient Care

Medication Talk - Expert Insights on Drug Therapy & Patient Care artwork

Updated COVID-19 Boosters

Nov 1, 202232 minAudio
ShareXLinkedInFacebookWhatsAppEmail

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Dr. Richard H. Dang, PharmD, APh, BCACP, FCPhA, from the University of Southern California and Dr. Elisha Hall, PhD, RD, from the COVID-19 Vaccine Policy Unit at the Centers for Disease Control and Prevention about COVID-19 vaccine boosters. Listen in as they answer your top questions about updated COVID-19 vaccine boosters. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board: Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor Health Douglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of Medicine Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science University None of the speakers have anything to disclose. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. Claim Credit 🗪 Send us Fan Mail Email us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Medication Talk is a production of TRC Healthcare. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here. Learn more about our product offerings at trchealthcare.com.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

NarratorWelcome to Medication Talk, the official podcast of TRC Healthcare, Homopharmacist Letter, Prescribers Letter, RX Advanced, and the most trusted clinical resources. On today's episode, we'll be listening in as our expert panel answers your top questions about updated COVID-19 vaccine boosters. Our guests today are Dr. Richard Dang from the University of Southern California and Dr. Alicia Hall from the COVID-19 vaccine policy unit at the Centers for Disease Control and Prevention. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board, Dr.

NarratorAndrea Darby Stewart from Honor Health, Dr. Douglas Powell from the University of Washington School of Medicine, and Dr. Craig Williams from the Oregon Health and Science University. This podcast is an extract from TRC's Emerging Recommendations panel webinar. Each month, experts and frontline providers discuss current medication therapy topics and practical recommendations to include in TRC's Letter articles. The full webinar originally aired on September 19, 2022.

CE NarratorAnd now, CE information.

NarratorPlease log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. Now let's join TRC editor, Dr. Lori Dickerson, and start our discussion.

Lori DickersonAnd to get us started, we have lots of questions coming up about the updated COVID-19 boosters. And so, Alicia, could you just briefly talk about the current state of the COVID-19 pandemic in terms of outcomes such as cases and hospitalizations and deaths, as well as the current rates of vaccination?

Elisha HallYeah, so as of today, the new daily average of cases is around 54,000. Hospitalizations is around 3,900, and deaths are 360. That's the new daily average. And as for rates of vaccination, fully vaccinated overall is approximately 79%. And for the first booster overall is around 49%, with the highest vaccination rates among older groups and sort of decreasing as we go down.

Elisha HallWe don't yet have bivalent data up on our COVID data tracker. So I'll just note that if you bookmark that page and keep your eye on it, we hope to have numbers on bivalent booster vaccination rates posted in the near future.

Lori DickersonOkay, great. Thank you for that overview, Alicia. And just to let us know globally where we are across the nation. And, you know, Doug and Craig, I did want to hear from both of you also. And how has uh your COVID-19 caseload changed in your health systems in recent weeks? So, Craig, why don't you go ahead and get started?

Craig D. WilliamsYeah, I'd say, you know, speaking on the hospital side, numbers still remain uh very modest and relatively low by uh last kind of 18 months standard. So as Omicron has taken over, we we are seeing less severe disease and less hospitalizations. But we are, you know, we're seeing the evidence of the older vaccines um being a bit less effective. So we're seeing a shift. Now we're about 50-50 vaccinated versus unvaccinated people being hospitalized. So we are seeing more people who got the vaccine being hospitalized, but almost always there's multiple comorbidities there. So you know, we're thankful that Omicron is more mild, but but the older vaccines don't work quite as well and our really susceptible patients are getting sick and getting hospitalized with it.

Lori DickersonAnd Doug, what's been your experience?

Douglas S. PaauwWe we're having about in our in our three hospital system, about 30 to 35 patients hospitalized a day, or that that's a census. And we we peaked at about 200 during during other surges. But but more striking is we have nobody in the ICU. I mean, we have one, maybe two patients throughout our three hospital systems with COVID in the ICU. So we've certainly seen a diminution of the most severe disease, and almost all the people who have ended up in the ICU have been non-vaccinated. Like Craig said, we we're similar to about a 50-50 split on the people who are hospitalized.

Lori DickersonOkay. Well, appreciate that overview uh to set the stage for our discussion. And so let's actually dig in now to the new bivalent COVID-19 boosters. And Richard, to get us started with this specific part of our discussion, can you just review which vaccines are now available as bivalent COVID-19 boosters and what ages are those authorized for?

Richard H. DangSo we currently have two uh brands of the bivalent COVID-19 vaccines that are available, one from Pfizer and BioNTech. The Pfizer bivalent vaccine is currently authorized for ages 12 years and older. And the second one would be the Moderna bivalent vaccine, and that one has been authorized for ages 18 years and older.

Lori DickersonOkay, and so that's consistent with what we have here in our article. And I guess some questions that sort of surround that, Alicia, for you, jumping a little bit ahead, but um wondering if you could comment briefly on the role of the monovalent or original COVID-19 boosters now that we have uh these new bivalent boosters.

Elisha HallYeah, so right now there actually isn't much of a role for the monovalent or original boosters. The Pfizer in ages 12 years and older, and the Moderna in ages 18 years and older for the monovalent booster, those have been removed from the EUA and those age groups. So they should not be used as um booster doses in those age groups. Really, the only one left that is recommended for a monovalent um booster is the 5 to 11 age group, specifically those who have received a primary uh Pfizer series in that age group.

Elisha HallGotcha.

Lori DickersonFollowing on from that, when do you expect authorization of these boosters for the younger age groups?

Elisha HallSo we don't have an anticipated date for FDA's authorization at the September 1st meeting. ACIP did, however, discuss data about updated boosters with the context of um ages five years and older. So currently, FDA and CDC will be reviewing that data and could update authorizations or recommendations in the somewhat near future. Um, but unfortunately, no it no exact date at this time. Gotcha, gotcha.

Lori DickersonWe can't predict that specifically. I understand that. And then one more question that's just come in about uh some of the other vaccines. And this audience member is asking, will there be bivalent boosters coming for the JJ and NovAX vaccines? And so Alicia, could you address that also?

Elisha HallYeah, so JJ, we're not aware of a bivalent for JJ. For Novavax, it is expected that FDA will review data on safety and effectiveness of a monovalent Novavax booster as an alternative to mRNA, particularly for those who would not otherwise be eligible due to, for instance, contraindication to an mRNA vaccine. The reason for Novavax monovalent being sort of the next step is because the Novavax bivalent is only in very early clinical trials, and we don't really have an alternative right now for folks in this age group if they're allergic to an mRNA.

Elisha HallGotcha. Okay, very good.

Lori DickersonWell, that sets the stage uh for what we have available. And so, Richard, we have uh noodled a lot with our wording here about defining what a bivalent booster is and and uh defining what they cover. And you'll notice in our article we say they'll still cover the original SARS-CoV-2 virus, but also Omicron BA4 and BA5, the variants currently circulating. And so I just wanted to confirm that you agree with that wording as the explanation for a bivalent booster.

Richard H. DangYeah, absolutely. That explanation looks great. The bivalent uh contains coverage against the original and uh the Omicron BA4-5 strain. So bivalent is covering two different types of strains to provide broader protection.

Lori DickersonGreat. And Alicia, um, our next uh point that we have in the article is about efficacy. And again, there's been a lot of uh discussion about human data and animal data and how these have been tested. So could you just briefly explain how efficacy is tested with these boosters and how efficacy was defined in terms of uh you know the ACIP's uh decision making?

Elisha HallUm so both both Moderna and Pfizer evaluated the immune response through human clinical trials for BA1 bivalent vaccines compared to the original monovalence, and in both cases, um bivalent vaccines increased the immune response in those who completed a primary series and previous booster compared to the original, the bivalence demonstrated a superior response to Omicron, other SARS-CoV-2 variants, and at least a non-inferior response to the ancestral strain. And the BA1, sort of the decision making here, the BA1 data were extrapolated to make a decision on the BA4, BA5 bivalence.

Elisha HallCompared with the original strain, all Omicron sublineages have 21 shared mutations, which are located on the binding site. Basically, the take-home here is there was so few differences in the genetic code for BA1 and BA4. That it was logical to extrapolate BA1 data to BA4-5. So I know it's come up a lot that, oh, there's only animal study data. That's not really the case.

Lori DickersonI appreciate you clarifying that because that has been a question that we have had, and that's why we took the space and the article to really try to explain that. And I appreciate you reiterating what we've got here and giving a little bit of more detail for our listeners. So that's great. And you know, Richard, we have some audience questions coming in too related to this bivalent booster, and it relates to side effects. And this audience member is asking will side effects be similar with the COVID-19 bivalent boosters similar to the monovalents.

Lori DickersonAnd uh so how would you address that question, Richard?

Richard H. DangYeah, absolutely. The side effect profile are very similar for both the monovalent and bivalent vaccines. I do also want to note that this side effect profile data for the bivalent vaccine was also extrapolated from the BA1 trials that were conducted. So similar to what Alicia said about the efficacy, we're extrapolating that information to the BA4-5 bivalent vaccine. But when you look at that information for the BA1 bivalent vaccine, the side effect profile is very similar, very similar rates of local site reactions and systemic reactions.

Richard H. DangAnd actually, in some cases, they might actually have lower incidents that were reported in those BA1 trials.

Lori DickersonGot it. Well, that's great to explain, and I think addresses the questions that our folks are getting and hopefully helps our viewers know how to address those questions with patients. And so, Andrea, I wanted to call on you now. Um, I'm curious, are patients in your practice asking about these new boosters yet? And and uh did have they been sharing any concerns or enthusiasm for these of those who I guess previously had enthusiasm for vaccines?

Andrea Darby StewartUm you know, there's there's a healthy amount of do we have to that's going on in the practice, which I find kind of entertaining. Um so yes, I've got plenty of people who are going out and seeking these vaccines, and I get these lovely notifications from pharmacies that my patients have received them and it makes me happy. And then when I uh talk with my patients in the clinic, um they're generally fairly receptive. Um, those are my patient cohorts. When I talk to our general patient population in our residency program, I would say the uptake for the booster is about the Arizona average, which is far less than 30% uh being boosted in the state.

Andrea Darby StewartAnd I don't know that that's going to increase significantly.

Lori DickersonI appreciate that perspective. And Doug, I'm curious uh in your outpatient practice, uh, what are your patients asking about with respect to the boosters?

Douglas S. PaauwYeah, my practice, they I have a lot of patients that are immunosuppressed, both HIV and patients on on biologics, and and they they are so excited about getting it. And they, you know, and and surprising to me, you know, the people I've seen this week had already gotten the booster. They've gotten it the second it became available. As far as our city, uh, you know, I think our numbers are fortunately a bit higher than what Andrea deals with, but but we still have some people that are are quite hesitant and feel like they've done their work by getting getting an original series and maybe a booster, but you know, my my population really wants the booster.

Lori DickersonYou know, Alicia, a question is coming in um about, you know, with so many people in the United States having had Omicron, you know, how can we frame this to get buy-in um for this new booster? And I'm curious about how you would address that concern.

Elisha HallYeah, that's actually a great question. Um so we know that vaccination still has a benefit in studies with uh people who have previously had not just Omicron, but SARS-CoV-2 infection, we're still finding that um a booster helps with the immune response. Um I think possibly a point to drive home that might make folks more willing is um we do have a recommendation that they may space it out um three months later.

Elisha HallSo then they're getting the most sort of bang for their buck with that booster and not having to immediately get it, but get it maybe a little later when the protection has waned.

Lori DickersonOkay, great. And we're gonna talk a little bit about that timing. So that's a great segue. Um and Alicia, I'm gonna ask you uh to now we're gonna talk about what the ACIP recommendations are for the new Bivalent COVID-19 boosters. And so we make the statement in our article to offer a bivalent COVID-19 booster to patients age 12 and up who finished the primary series or got a booster at least two months ago, regardless of the number of prior COVID-19 boosters or infections. And so wondering what you think about that recommendation.

Elisha HallYeah, I that looks exactly right. Um I would just echo what you've already put there. And then, of course, um, we have that extra three-month consideration for those who have had an infection.

Lori DickersonOkay, we're gonna um talk about that timing bit. And in fact, um uh we're we're gonna remove the word or infections at the end of this uh line in the article because really this is about number of uh boosters and not necessarily about timing. And so we do talk about timing a little bit further down. Um but Richard, I guess just wanted to hear from you too uh about what we have there after the ellipse, regardless of the number of prior COVID-19 boosters. Is this consistent with your thinking about the new bivalent boosters?

Richard H. DangThat is consistent, yeah. And I think the you know the message we heard from the CDC is basically this is a quote unquote reset of the number of booster doses. So, irregardless of how many you've had before, everyone should get the bivalent vaccine.

Lori DickersonOkay. Uh let's actually um skip ahead a little bit here and talk about prioritizing different groups for the bivalent COVID-19 boosters. And so we make the statement to vaccinate eligible patients at higher risk of severe COVID-19 age over 65, immunocompromised as soon as possible. Um, and you know, uh as a little take beyond uh what the uh CDC's recommendations are, Alicia. So what can you just comment a little bit on the CDC's stance on prioritizing different groups for the bivalent boosters?

Elisha HallYeah, so um CDC has essentially um left uh prioritization up to states and jurisdictions just because at the it's it wasn't quite exactly how it was at the very beginning of the pandemic when there was a very, very small supply. Um I know there have been a bit of supply issues. Um so there wasn't really the need for the prioritization criteria there was in the beginning.

Lori DickersonSo, Richard, just to I guess hear from you, um, if we you know, in in with our letters, we try to go beyond the guidelines and give a little bit, you know, more clarification about what you should do in your busy practice. And so do you agree with our statement here to you know try to prioritize these folks uh who might be uh you know more vulnerable uh for future infection? What are your thoughts here?

Richard H. DangYeah, I think I would agree with that. You know, I think the Bob blanket recommendation is that everyone get the bivalent vaccine two months after your last dose, but we're also taking a look at, from a clinical perspective, individual risk profiles. And I do think that those at the highest risk, you know, those who are immunocompromised, those who are elderly, um, you know, that those individuals definitely prioritize and get those vaccine as soon as possible, while those who maybe have had previous infection or who are younger and healthier could wait a little bit before they get their bivalent booster.

Richard H. DangBut at the end of the day, everyone should be getting it.

Lori DickersonOkay, great clarification there. And I think that's in line with our wording. If we go to the timing question next, you know, and of course, the CDC's recommendation is to uh have a window of at least two months between um last booster or dose and the new bivalent vaccine. But we make the statement here to consider waiting three to six months for other patients, again, maybe not these immunocompromised folks, uh, but lower risk patients. For example, it's okay if lower risk patients wait a couple of weeks before a large gathering, for example, or up to three months after a prior COVID-19 infection.

Lori DickersonAnd so, Richard, what are your thoughts on this guidance? Again, to try to just go a little bit further than the guidelines.

Richard H. DangUh yeah, no, I think I would agree with that. Um, I'm not sure how I feel about up to six months. I think you know, three months would probably be be good for me. Um, I think it's also, you know, at an individual level, hard to tell, you know, hard for people to time it. We don't want to try to time when the next peak is going to happen. I think from a public health standpoint, we do want to encourage everyone to get vaccinated for you know prior to the winter season, which is when we may or may not see a peak. Um so you know, I would lean more towards the three months for some of my lower risk uh patients.

Lori DickersonOkay. And Alicia, do you have any thoughts on this wording that we have here and that three to six month timing window?

Elisha HallUm so I don't have um too many thoughts on this. I mean, uh the CDC has the uh at least two months recommendation. Uh generally, um I I think this won't actually be an issue because a majority of individuals under 50 are actually at least six months out from their last dose. So I think it's gonna be sort of the minority that folks even need to weigh the decision of at least two months or later than two months because most people are already well past that point. Okay.

Lori DickersonNow, Andrea, I want to hear from you. You've chatted over that you have some concerns about this wording. So tell tell me what you're thinking.

Andrea Darby StewartSo my concern is that um we are headed into the fall and the winter when we're going to anticipate, and again, we don't know what's going to happen with this virus, but we're gonna anticipate, we've got two years of experience that this will ramp up. And I'm a little worried about telling our lower risk patients that they can delay a vaccine, that if we have them physically present and we can give it, or we have their ear and we can get them engaged enough to go get a vaccine at an external place like a pharmacy.

Andrea Darby StewartWhy would I tell them to delay that? Because I know what happens when I ask them to delay other types of vaccines, or when I say, Oh, wait for two months and come back and see me, they may or may not show up. And I frankly, from a public health perspective, would rather get as many people boosted right now and working on the theory that I can hopefully reduce the burden of disease going into this uh winter than say, oh, well, you know, go ahead and wait. Now, if somebody's hesitant and they need a little bit of leeway, yeah, I'm gonna give them that.

Andrea Darby StewartUm, but if somebody is interested, I'm not gonna say, oh, you're young and healthy, go ahead and wait for three to six months.

Lori DickersonI I'm really glad you brought this up. Yeah, go ahead.

Richard H. DangI actually I I would agree, I want to clarify, I would I actually agree with Andrea. So I wouldn't turn anyone away who's coming asking for it. I would keep that recommendation in my back pocket for people who are maybe questioning or hesitant.

Lori DickersonThis has been, of course, a very fast-moving, changing article that we've prepared over the last uh 15 days or so. And originally I think there were concerns about supply, I mean originally being just a few days ago, but I'm hearing um, you know, you from you, Alicia, that perhaps that isn't going to be the an issue and we may not need to make this sort of recommendation. So I think um we hear your hesitancy here, and I think we know what to do to adjust this to be more clear and not convey that we we want people to wait for uh for reasons if they if they're ready to go.

Lori DickersonSo we'll work on that. And I want to go back to which vaccine to give, uh, because we do have a bunch of questions coming in. We also make the point to give whichever age-appropriate bivalent booster you have in stock. And so, you know, not having people wait for Pfizer or Moderna, but give whatever you have in stock. And uh, Andrea, you had a question too about mixing and matching Novavax primary with one of the um Pfizer and Moderna boosters. And so, Alicia, could you comment on uh if there's a preference of one bivalent booster over another and uh this concept of mixing and matching?

Elisha HallYeah, so I would absolutely echo what you have. Um, whatever is in stock is the one they should get provided as age appropriate. Um, although we don't have specific data on bivalent for mix and match, we know from mix and match studies with monovalent mRNA vaccines that effectiveness and reactogenicity is similar. With either a monovalent Pfizer or a Moderna booster. So we would expect this to be similar for mRNA bivalence since it's the same platform and not too different. The advantage of mixing or having the same is probably very minimal when we're comparing two mRNA vaccines.

Elisha HallOkay.

Lori DickersonVery good. And uh I guess also just wanted to hear from you, Doug, or what are your plans for offering boosters in your practice? Is this uh is all this in line with sort of the the approach that you guys are thinking of using and rolling out in your system?

Douglas S. PaauwYeah, we we have them, we have the bivillin available and have been giving it. We only have the the Pfizer, so uh you know, we've been giving that to people, whether they regardless what their first series was. And uh so it and it's been working fine. I haven't had any pushback. I I was a little worried I'd have people that were so strong about about, you know, I've always gotten Moderna, but but I have had no pushback at all.

Lori DickersonCraig, we have an audience question coming in here about what's been happening in the inpatient setting. Um, and again, uh just curious if in your health system are you all giving the bivalent boosters yet? Um, or you know, how is that how is that rolling out?

Craig D. WilliamsOh yeah, it's actually rolling out kind of as we speak. So within the last just week that has started, it'll be a little different than the kind of COVID vaccine rollout of 18 months ago, or it was really pretty pushed, but certainly strongly encouraged, and it was part of kind of the uh admitting the patients. Uh now it'll be a bit more it's available and we'll be encouraging it, but um a little different approach with the with the patients. But it's just rolling out kind of as we speak here. Yeah.

Lori DickersonOkay, very good, very good. I'm gonna jump up to an audience question that's coming in, getting actually several questions come in about what to do for unvaccinated patients. And so the question is why aren't we using these new bivalent vaccines for the primary vaccine series? As a recommendation, of course, is to uh use the current primary vaccine series uh with the monovalents before giving the booster. And so, Alicia, could you comment on uh why that decision was made and um if you think that will change in the future?

Elisha HallYeah, and um I can sort of partially comment here um because um a big part of this is what FDA authorizes, and I don't know um all of what goes into their decision, um, but I would say that the monovalent still builds a foundational immune response and it does demonstrate neutralizing antibody titers to Omicron, although of course not as high as the bivalent, which includes um the mr mRNA uh for omic uh omicron BA4, BA5.

Elisha HallUm, and of course, another part of it is as I mentioned, FDA has not authorized this yet. So we can't issue recommendations for a vaccine that is not authorized for that use. Um, but recommendations may change over time as we get additional information on the bivalent vaccine as the primary series. So even though it's not happening now, it's not to say it won't happen in the future.

Lori DickersonOkay, very good. And Andrea, a question for you uh that's coming in from some audience members too. And I'm curious what your thoughts are. Do you think that these new bivalent boosters will impact decisions in your still unvaccinated patients? Do you think that this is going to shift that population at all?

Andrea Darby StewartHonestly, I don't. Um, I'm a little worried about the fact that we've added another booster, and even my patients who were very enthusiastic adopters of both the primary series and one or two recent boosters are kind of giving me the deep sigh uh if when we talk about this one. So I'm I'm worried that at least in the in my state and given where I live, that this may not uh move those people who have chosen not to vaccinate.

Lori DickersonWell, I think we'll be watching that to see if uh there is any movement amongst this group or how we could continue to try to address that. And I'm curious, uh Richard, is this something that you're working on addressing with your learners and how you know the new booster could could be uh used as a talking point to try to move some of those vaccine hesitant or resistant folks?

Richard H. DangYeah, I think we're always looking to use this as a re a point to kind of reinforce with our population who might be hesitant. And I think luckily around where I'm at, we have fairly high uh acceptance of vaccination rates, but we we do want to try to get into those who are more hesitant.

Lori DickersonOkay, very good. Uh okay, so um just some practical questions, Richard. Um, we make the statement to uh of course catch patients up when giving flu or other needed vaccines. And of course, this points to your concern also, Andrea, that we're saying if they're there and they're in the office and getting other vaccines or in for any reason we want to go ahead and catch them up and give them other needed vaccines at the same time. And so, Richard, just to confirm our wording here to give injections at least one inch apart or in different limbs, especially with high dose or adjuvanted flu vaccines.

Lori DickersonAnd I just want to clear and make sure that that's wording that um that is in line with your teaching and practice.

Richard H. DangYeah, that is that's in line. So it we know that it's okay to co-administer COVID vaccines with other vaccines, and it is a really great opportunity to catch up on any other routine ones that are needed. Flu, tetanus, and the ones you mentioned. Um, there is a recommendation to separate injection site at least one inch apart if given in the same deltoid muscle. And then with the um certain uh formulations of influenza, the adjuvant and high dose, due to the higher potential side effects, they do recommend separating uh the administration in different limbs. Uh, there's one consideration for co-administration of COVID vaccine, though, with the orthopox virus vaccine, which is being used for a monkeypox.

Richard H. DangUm, so for that particular um co-administration, there is a consideration to uh consider separating the doses by four weeks in um adolescent and young males due to potential risk of myocarditis.

Lori DickersonOkay, great clarification. I'm glad you brought that up. Thank you for that. And um, since I think uh that's not being done in a lot of our settings, um probably our folks won't get get have have that concern, but I am um glad that you that you did bring that point up.

Richard H. DangIt was relevant to our site because we actually opened a community-based clinic where we offered flu, COVID, and monkeypox vaccines.

Lori DickersonYeah, there you go. Yeah, things are changing rapidly, right? Absolutely. Um, you know, Alicia, another question that's coming in and relates to the next line in our article is about how many bivalent boosters should folks get? And so we make the recommendation that for now to give just one bivalent booster, additional doses aren't recommended even for immunocompromised patients. Uh and so curious, um, is that uh where you see this is for at least for now with just one single booster?

Elisha HallYeah, that's that's where we see it for now. And that's also all it's authorized for. So very important to follow the authorization. An annual uh vaccine similar to flu is certainly a possibility. Um we we just kind of sort of have to wait and see what happens and and monitor monitor the situation closely because the context could change.

Lori DickersonWe are getting a lot of questions uh as we have been preparing this article. Also, folks are asking, you know, is this going to be similar to the flu? Are we set is this shift setting us up for annual boosters? And so, Richard, what are your thoughts there and how you would answer that question for for your patients?

Richard H. DangI think we're gonna have to wait and see to see how it pans out. But based on the last few years, it it seems possible we may be headed towards an annual uh vaccination, but we don't have the data yet to make that statement conclusively.

Lori DickersonOkay. Um, Richard, we do have some wording here about dosing um to use 0.3 mls with Pfizer or 0.5 mls or 50 mics with Moderna and to uh store the boosters in the same manner as which the originals are stored. And I assume that you agree with that wording, and but just wanted to confirm with you that that's the way that you see it also.

Richard H. DangThat is how I see it, yes.

Lori DickersonOkay, very good, very good. The last question I have is about cost, and so we make the statement at the end that uh keep in mind COVID-19 vaccines are are no cost to patients until at least January 2023. And um, that includes admin fees if not covered by payers. And I wanted to confirm with you, Richard, uh, about this wording um and uh also specifically to confirm um uh you know the wording about pharmacy administration fees.

Richard H. DangYeah, that would be my understanding, at least until the uh federal funds were run out. Um and then even after that, I would I would kind of personally fully expect health plans to decide to cover uh the vaccine administration fees because it would be in their best interest to reduce their costs.

Lori DickersonAnd Alicia, anything to add to the cost cost discussion here, or is this consistent with what you understand also? Consistent with what I understand. Yep.

NarratorWe hope you enjoyed and gained practical insights from listening into this discussion. Now that you've listened, you can receive CE credit from Pharmacist Letter. Just log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. If you're not yet a Pharmacist Letter subscriber, find out more about our product offerings at TRCHealthcare.com. Be sure to follow or subscribe, rate, and review this show in your favorite podcast app. It helps spread the word about our show and is a great way for you to let us know how we're doing. You can also reach out to provide feedback or make suggestions by emailing us at contact us at trchealthcare.com.

NarratorThanks for listening to Medication Talk.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Navigating Obesity Treatment

    Nov 1, 202634 minAudio

    Listen in as our expert panel walks through today’s full range of obesity treatment options - from older agents like orlistat and phentermine/topiramate to the latest GLP-1 therapies - and how to match the right...

    Credit the people on this episode

  2. Feed Drop: Toxic Yellow Oleander in Weight Loss Products

    Oct 15, 202624 minAudio

    A bonus episode from our sister show, Natural Medicines: Evidence in Practice. Weight loss supplements labeled tejocote, Nuez de la India, or Brazil seeds have been found to contain toxic yellow oleander, and as few as...

    Credit the people on this episode

  3. Managing Poisonings

    Oct 1, 202633 minAudio

    Poisonings are a significant public health concern - in 2024 alone, U.S. poison centers received over 2 million reported exposures. Listen in as our expert panel of toxicologists and poison-center specialists discusses...

    Credit the people on this episode

  4. Decoding the Lipid Guidelines

    Sep 1, 202633 minAudio

    Listen in as our expert panel breaks down what clinicians need to know about the 2026 dyslipidemia guidelines, such as the role of lipoprotein a, apolipoprotein B, and coronary artery calcium scoring. Plus, you'll walk...

    Credit the people on this episode

  5. Estimating Kidney Function in Chronic Kidney Disease

    Aug 1, 202633 minAudio

    Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You’ll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust...

    Credit the people on this episode